Glenmark pharma launches generic version of Novartis' heart failure drug

Opens floodgates for more generic launches; 40 new brands expected

Photo: Reuters

Photo: Reuters

Sohini Das Mumbai
India’s Rs 20,000-crore cardiac drug market is in for a shake-up as generic launches of Novartis’ heart-failure drug Vymada begin. Mumbai-based Glenmark Pharmaceuticals on Monday announced the launch of their own brand of Sacubitril-valsartan tablets Sacu V, priced between Rs 19-35 per tablet.

Sheetal Sapale, president (marketing), AIOCD-AWACS said that at least 40 more brands are expected to be launched in this category, leading to a price erosion of at least 50 per cent.

Earlier in December, JB Pharma, which had acquired the Azmarda brand from Novartis AG, Switzerland for the India region for a consideration of Rs 246 crores in April 2022, had slashed its prices by half to Rs 39.6 per tablet. Only four companies were marketing Novartis’

First Published: Jan 17 2023 | 4:44 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to